The board of the Hyderabad-based pharmaceutical company also recommended a final dividend of ₹30 per share for FY26.
Divi’s Laboratories reported a 13.4% year-on-year rise in net profit for the January-March quarter of FY26 at ₹751 crore, ahead of the CNBC-TV18 poll estimate of ₹713 crore.
Revenue for the quarter rose 9.5% from a year earlier to ₹2,831 crore, but was slightly below the CNBC-TV18 estimate of ₹2,859 crore.
Earnings before interest, taxes, depreciation and amortisation (EBITDA) increased 5.4% year-on-year to ₹934 crore, with EBITDA margin slipping to 33% from 34.3% a year ago. CNBC-TV18 estimates pegged margins at 34.2%.
The board of the Hyderabad-based pharmaceutical company also recommended a final dividend of ₹30 per share for FY26.
